clinical trial · NCT07108270
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
GlaxoSmithKline·phase2·recruiting·n = 30
Neoplasms, EndometrialDostarlimabCarboplatinPaclitaxel
brief summary
The goal of this clinical trial is to see how well dostarlimab works when administered with the chemotherapy drugs carboplatin and paclitaxelin in treating EC in Chinese participants. The study aims to understand the treatments effectiveness, safety, how the drugs behave in the body, and whether it causes any immune reactions.
started
Nov 27, 2025
primary completion
Mar 31, 2030
completion
Mar 31, 2030
last updated
Dec 22, 2025
official title
A Phase 2, Multicenter, Open-label, Single Arm Study of Dostarlimab Plus Carboplatin-paclitaxel Followed by Dostarlimab Monotherapy in Participants With dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer in China (China RUBY)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol